SIGLEC9抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human plasma solution, Primary antibody: P08131(SIGLEC9 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P08131(SIGLEC9 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

SIGLEC9 (sialic acid-binding immunoglobulin-type lectin 9) is a transmembrane protein belonging to the SIGLEC family of immune-regulatory receptors, primarily expressed on myeloid cells like monocytes, macrophages, and neutrophils. It recognizes sialic acid-containing glycans on cell surfaces, transmitting inhibitory signals through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) to modulate immune responses. SIGLEC9 plays a dual role in balancing immune activation and tolerance. In physiological conditions, it helps dampen excessive inflammation by promoting phagocytic clearance of apoptotic cells and suppressing pro-inflammatory cytokine release. However, in pathologies like cancer, chronic inflammation, or sepsis, its overexpression is often exploited by diseased cells to evade immune detection. For instance, tumor cells expressing sialylated ligands engage SIGLEC9 on infiltrating myeloid cells, inducing immunosuppressive phenotypes that facilitate tumor progression.

SIGLEC9 antibodies, either antagonistic or agonistic, are investigational tools and therapeutic candidates. Blocking antibodies aim to disrupt SIGLEC9-mediated immunosuppression in cancer immunotherapy, potentially enhancing anti-tumor immunity. Conversely, agonist antibodies may treat inflammatory disorders by amplifying SIGLEC9’s anti-inflammatory signals. Challenges include optimizing specificity to avoid off-target effects and understanding context-dependent signaling. Research continues to explore its tissue-specific roles, ligand interactions, and crosstalk with other checkpoint receptors like PD-1/PD-L1.